As a Principal Scientist at Zumutor Biologics Pvt. Ltd., a biotech startup, I’ve played a pivotal role in shaping and executing strategic scientific programs under resource-constrained conditions typical of startup ecosystems. My contributions include:

Program Design & Innovation: I led the development of multiple monoclonal antibodies, including the construction of a proprietary antibody library and the establishment of a yeast display platform—both foundational technologies for therapeutic discovery in healthcare and diagnostics.

• End-to-End Program Management: I oversaw the entire lifecycle of a molecule from discovery to Phase I clinical trials, coordinating with CROs for ex vivo assays, cross-reactivity studies, and cell-based assay development. These efforts culminated in a successful IND application to the USFDA, demonstrating my ability to manage complex regulatory and scientific workflows.

• Startup Leadership & Strategy: Operating within a startup, I’ve had to balance innovation with strategic execution. Holding ESOPs reflects my deep commitment to the organization’s growth and long-term vision. I’ve helped shape the scientific roadmap while mentoring teams and fostering a collaborative culture.

• Government Grants: I have successfully applied for and secured competitive grants from national funding bodies that supported early-stage biologics development, including antibody engineering and immuno-oncology research. These grants enabled us to expand our R&D capabilities and accelerate pipeline progression.

• Private Entity Support: I have also engaged with private foundations and innovation-driven funding platforms, crafting proposals that aligned Zumutor’s scientific vision with their investment priorities. This resulted in additional funding that supported technology validation and preclinical studies.

• Strategic Grant Writing & Execution: Beyond securing funds, I’ve been deeply involved in designing project plans, defining milestones, and ensuring compliance with grant deliverables. My ability to translate complex scientific goals into fundable narratives has been instrumental in building trust with funding agencies.

• Impact on Innovation: These fundraising efforts have directly contributed to the successful advancement of a monoclonal antibody into Phase I clinical trials, showcasing the tangible impact of well-managed grant programs on therapeutic innovation.

This experience has not only strengthened my understanding of the funding landscape in healthcare and biotech, but also honed my ability to align scientific innovation with strategic financial planning.